Lynparza (AstraZeneca Pharmaceuticals LP)
Welcome to the PulseAid listing for the Lynparza drug offered from AstraZeneca Pharmaceuticals LP. This Poly(ADP-Ribose) Polymerase Inhibitor [EPC],Poly(ADP-Ribose) Polymerase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | AstraZeneca Pharmaceuticals LP |
NON-PROPRIETARY NAME: | olaparib |
SUBSTANCE NAME: | OLAPARIB |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Poly(ADP-Ribose) Polymerase Inhibitor [EPC],Poly(ADP-Ribose) Polymerase Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | CAPSULE |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2014-12-24 |
END MARKETING DATE: | 0000-00-00 |
Lynparza HUMAN PRESCRIPTION DRUG Details:
Item Description | Lynparza from AstraZeneca Pharmaceuticals LP |
LABELER NAME: | AstraZeneca Pharmaceuticals LP |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 50(mg/1) |
START MARKETING DATE: | 2014-12-24 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0310-0657_2586bfb2-e1a6-41f2-b3ee-f78320a5c6fa |
PRODUCT NDC: | 0310-0657 |
APPLICATION NUMBER: | NDA206162 |
Other OLAPARIB Pharmaceutical Manufacturers / Labelers: